Pediatric case of acquired progressive lymphatic anomaly treated with sirolimus

Pediatr Int. 2023 Jan;65(1):e15497. doi: 10.1111/ped.15497.

Authors

Sayano Komamizu¹, Michio Ozeki¹, Daichi Hayashi¹, Saori Endo¹, Yumiko Hori-Hirose^{2

3}, Satoru Sasaki⁴, Hidenori Ohnishi¹

Affiliations

¹ Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu, Japan.
² Department of Central Laboratory and Surgical Pathology, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
³ Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.
⁴ Department of Plastic and Reconstructive Surgery, Center for Vascular Anomalies, Tonan Hospital, Sapporo, Japan.

PMID: 36749179
DOI: 10.1111/ped.15497

No abstract available

Keywords: acquired progressive lymphangioma; benign lymphangioendothelioma; lymphatic malformation; mTOR inhibitor; vascular anomaly.

MeSH terms

Child
Humans
Immunosuppressive Agents / therapeutic use
Lymphangioma*
Lymphatic Abnormalities* / diagnosis
Lymphatic Abnormalities* / drug therapy
Sirolimus / therapeutic use

Substances

Sirolimus
Immunosuppressive Agents

Grants and funding